The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP.
Pilarski R, et al.
PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.
PLoS One. 2012.
PMID: 22662244
Free PMC article.